Neurogene (NGNE) Cash from Operations (2013 - 2026)

Neurogene has reported Cash from Operations for 14 years, with the latest figure at 26100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 25.64% year-over-year to 26100000.0; the trailing twelve-month figure through Mar 2026 stood at 82526000.0 (down 18.36% YoY), and the FY2025 full-year result was 77200000.0, down 9.34% from the prior year.
• Cash from Operations for Q1 2026 stood at 26100000.0, down from 17500000.0 in the prior quarter.
• The five-year high for Cash from Operations was 9282000.0 in Q2 2023, with the low at 26100000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 16361705.88 across 5 years, with a median of 16922000.0 in 2023.
• Annual changes were most pronounced in 2023 — Cash from Operations increased 17.81% — and 2024, when it tumbled 70.76%.
• Neurogene's Cash from Operations stood at 18150000.0 in 2022, then rose by 6.77% to 16922000.0 in 2023, then fell by 3.39% to 17496000.0 in 2024, then decreased by 0.02% to 17500000.0 in 2025, then slumped by 49.14% to 26100000.0 in 2026.
• The last three Cash from Operations figures came in at 26100000.0 (Q1 2026), 17500000.0 (Q4 2025), and 19464000.0 (Q3 2025), per Business Quant data.